[HTML][HTML] Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma-a meta-analysis of 2,596 trial patients
N Weinhold, HJ Salwender, DA Cairns, MS Raab… - …, 2021 - ncbi.nlm.nih.gov
Hemoglobin (g/L) 865 110 99 97< 0.001 1716 108 105 98< 0.001 (95, 123)(88, 114)(88,
113)(95, 120)(93, 117)(89, 109) Platelets (x109/L) 880 254 224 186< 0.001 1716 241 222 …
113)(95, 120)(93, 117)(89, 109) Platelets (x109/L) 880 254 224 186< 0.001 1716 241 222 …
Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications
The remarkable genetic heterogeneity of multiple myeloma poses a substantial challenge
for proper prognostication and clinical management of patients. Here, we introduce MM …
for proper prognostication and clinical management of patients. Here, we introduce MM …
Risk factors in multiple myeloma: is it time for a revision?
J Corre, NC Munshi… - Blood, The Journal of the …, 2021 - ashpublications.org
Although therapeutic strategies have been adapted to age and comorbidities for a long time,
almost all multiple myeloma (MM) patients currently receive similar treatment, whatever their …
almost all multiple myeloma (MM) patients currently receive similar treatment, whatever their …
[HTML][HTML] Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma
LB Leypoldt, D Tichy, B Besemer, M Hänel… - Journal of Clinical …, 2024 - ncbi.nlm.nih.gov
PURPOSE The GMMG-CONCEPT trial investigated isatuximab, carfilzomib, lenalidomide,
and dexamethasone (Isa-KRd) in transplant-eligible (TE) and transplant-noneligible (TNE) …
and dexamethasone (Isa-KRd) in transplant-eligible (TE) and transplant-noneligible (TNE) …
Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities
N Abdallah, P Greipp, P Kapoor, MA Gertz… - Blood …, 2020 - ashpublications.org
A gain in chromosome 1q (+ 1q) is among the most common cytogenetic abnormalities in
multiple myeloma (MM). It is unclear whether+ 1q is independently associated with …
multiple myeloma (MM). It is unclear whether+ 1q is independently associated with …
[HTML][HTML] Game of bones: how myeloma manipulates its microenvironment
T Moser-Katz, NS Joseph, MV Dhodapkar… - Frontiers in …, 2021 - frontiersin.org
Multiple myeloma is a clonal disease of long-lived plasma cells and is the second most
common hematological cancer behind Non-Hodgkin's Lymphoma. Malignant transformation …
common hematological cancer behind Non-Hodgkin's Lymphoma. Malignant transformation …
Genome instability in multiple myeloma: Facts and factors
Simple Summary Multiple myeloma is an incurable blood cancer caused by the malignant
transformation of immunoglobulin-producing plasma cells. The mechanisms leading to the …
transformation of immunoglobulin-producing plasma cells. The mechanisms leading to the …
Role of 1q21 in multiple myeloma: from pathogenesis to possible therapeutic targets
J Burroughs Garcìa, RA Eufemiese, P Storti… - Cells, 2021 - mdpi.com
Multiple myeloma (MM) is characterized by an accumulation of malignant plasma cells (PCs)
in the bone marrow (BM). The amplification of 1q21 is one of the most common cytogenetic …
in the bone marrow (BM). The amplification of 1q21 is one of the most common cytogenetic …
Systems medicine dissection of chr1q-amp reveals a novel PBX1-FOXM1 axis for targeted therapy in multiple myeloma
N Trasanidis, A Katsarou, K Ponnusamy… - Blood, The Journal …, 2022 - ashpublications.org
Understanding the biological and clinical impact of copy number aberrations (CNAs) on the
development of precision therapies in cancer remains an unmet challenge. Genetic …
development of precision therapies in cancer remains an unmet challenge. Genetic …
Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents
Abstract Chromosome 1 abnormalities (C1As) are common genetic aberrations among
patients with multiple myeloma (MM). We aimed to evaluate the significance of C1As among …
patients with multiple myeloma (MM). We aimed to evaluate the significance of C1As among …